Physician profile
Charles Kivowitz
NPI 1942221072
$816.43
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $250 · 2021: $76.40.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $351.85 | 2019-2021 | |
| Amgen INC. | $191.35 | 2019-2020 | |
| Allergan, INC. | $64.53 | 2020 | |
| Glaxosmithkline, LLC. | $64.31 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.17 | 2019 | |
| Merck Sharp & Dohme LLC | $20.12 | 2020 | |
| Amarin Pharma, INC. | $19.53 | 2019 | |
| Genentech USA, INC. | $17.62 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.66 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.98 | 2019 | |
| Bardy Diagnostics, INC. | $15.28 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.03 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Kivowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.